Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

GSK2636771

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

GSK

Drug class:

PI3Kβ inhibitor

Related drugs:

‹

›

PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	GSK2636771 Sensitive: C3 – Early Trials GSK2636771 Sensitive : C3	GSK2636771 Sensitive: C3 – Early Trials GSK2636771 Sensitive : C3
PTEN mutation	Melanoma	PTEN mutation	Melanoma	pembrolizumab + GSK2636771 Sensitive: C3 – Early Trials pembrolizumab + GSK2636771 Sensitive : C3	pembrolizumab + GSK2636771 Sensitive: C3 – Early Trials pembrolizumab + GSK2636771 Sensitive : C3
HLA-A*02	Gastric Cancer	HLA-A*02	Gastric Cancer	GSK2636771 Sensitive: C3 – Early Trials GSK2636771 Sensitive : C3	GSK2636771 Sensitive: C3 – Early Trials GSK2636771 Sensitive : C3
PIK3R1 M326I	Gastric Cancer	PIK3R1 M326I	Gastric Cancer	GSK2636771 Sensitive: C3 – Early Trials GSK2636771 Sensitive : C3	GSK2636771 Sensitive: C3 – Early Trials GSK2636771 Sensitive : C3
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	pembrolizumab + GSK2636771 Sensitive: C3 – Early Trials pembrolizumab + GSK2636771 Sensitive : C3	pembrolizumab + GSK2636771 Sensitive: C3 – Early Trials pembrolizumab + GSK2636771 Sensitive : C3
PTEN deletion	Melanoma	PTEN deletion	Melanoma	GSK2636771 + ENUM004 Sensitive: D – Preclinical GSK2636771 + ENUM004 Sensitive : D	GSK2636771 + ENUM004 Sensitive: D – Preclinical GSK2636771 + ENUM004 Sensitive : D
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	GSK2636771 Resistant: D – Preclinical GSK2636771 Resistant : D	GSK2636771 Resistant: D – Preclinical GSK2636771 Resistant : D
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	GSK2636771 + A66 Sensitive: D – Preclinical GSK2636771 + A66 Sensitive : D	GSK2636771 + A66 Sensitive: D – Preclinical GSK2636771 + A66 Sensitive : D